Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
98.84
-1.21 (-1.21%)
At close: Feb 11, 2026, 4:00 PM EST
99.49
+0.65 (0.66%)
After-hours: Feb 11, 2026, 7:53 PM EST
Incyte Revenue
In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth. Incyte had revenue of $1.51B in the quarter ending December 31, 2025, with 27.84% growth.
Revenue (ttm)
$5.14B
Revenue Growth
+21.22%
P/S Ratio
3.75
Revenue / Employee
$1,807,750
Employees
2,844
Market Cap
19.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.03M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.67M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.72% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.38B |
| Moderna | 2.23B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 758.59M |
| Insmed | 447.02M |
| BridgeBio Pharma | 353.78M |
INCY News
- 12 hours ago - Incyte: Why The Market Is Overreacting To A Guidance 'Miss' - Seeking Alpha
- 1 day ago - Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Incyte weak 2026 revenue forecast heightens Jakafi patent concerns - Reuters
- 1 day ago - Incyte Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 12 days ago - Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
- 15 days ago - Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 20 days ago - What Investors Should Know Before Buying Incyte - Seeking Alpha
- 26 days ago - Incyte: Buy For The Turnaround, Stay For The Pipeline - Seeking Alpha